PMC6374873_01
Chest X-ray one and a half months after the initiation of everolimus treatment, showing no infiltrative shadows in both lung fields.
CRIU2019-2703871.001.jpg
PMC6374873_01_CRIU2019-2703871.001.jpg
fig1
At one and a half months after everolimus induction, the patient showed no remarkable respiratory symptom and no remarkable change was seen in the patient's chest X-ray (Figure 1).
(a) Chest X-ray two months after starting everolimus administration, showing diffuse infiltrative shadows in both lung fields. (b) Chest CT scan two months after starting everolimus administration, showing ground-glass attenuation with diffuse alveolar consolidation in both lung fields.
CRIU2019-2703871.002.jpg
PMC6374873_01_CRIU2019-2703871.002.jpg
fig2
Linear, reticular shadows were found in both lung fields during chest radiography (Figure 2(a)), and a chest CT revealed diffuse ground-glass opacities, thickening of the interlobular septa, and consolidation throughout both lung fields. Mild pericardial effusion was found, but there is no findings of suspecting cardiogenic pulmonary edema, which indicate acute respiratory distress syndrome (Figure 2(b)).